The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

BackgroundUnresectable advanced or recurrent gastric cancer patients have a poor prognosis. PD-1 monotherapy regimen and PD-1 combined chemotherapy regimen have become the standard third- and first-line treatment for advanced gastric cancer, respectively. However, the status of immune checkpoint inh...

Full description

Bibliographic Details
Main Authors: Jianzheng Wang, Yunduan He, Baiwen Zhang, Huifang Lv, Caiyun Nie, Beibei Chen, Weifeng Xu, Jing Zhao, Xiaojiao Cheng, Qingli Li, Shuiping Tu, Xiaobing Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
gastric cancer
sintilimab
nab-paclitaxel
second-line treatment
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.924149/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.924149/full

Similar Items